Y-mAbs Therapeutics, Inc. - Common Stock (YMAB)

Competitors to Y-mAbs Therapeutics, Inc. - Common Stock (YMAB)

Amgen Inc. 

Amgen is a leading biopharmaceutical company that competes with Y-mAbs specifically in the oncology space by developing biologic treatments for various forms of cancer. Amgen's well-established products and its commitment to advancing cancer therapies provide significant competition to Y-mAbs. While Amgen has a more extensive product lineup and greater market influence, Y-mAbs is focused on niche therapies which could pose unique competitive threats in specialized areas. However, overall, Amgen currently holds a competitive advantage due to its established market position.

Blueprint Medicines Corporation 

Blueprint Medicines specializes in targeted drug discovery and development, focusing on genomically-targeted therapies for cancer. They compete with Y-mAbs by also working on novel solutions for rare cancers, thereby capturing a similar niche market. However, Blueprint's competitive advantage is amplified by its strong partnerships, collaborative research holdings, and effectively managed pipeline that consistently attracts investor interest. This allows Blueprint to maintain a strong position, although Y-mAbs maintains unique offerings aimed specifically at pediatric cancer treatments.

Bristol Myers Squibb Company 

Bristol Myers Squibb (BMY) competes with Y-mAbs primarily in the field of oncology and immunotherapies. BMY has a strong portfolio of established cancer therapies and a robust pipeline, which includes innovative treatments that could provide significant competition to Y-mAbs' radiopharmaceuticals targeted at neuroblastoma and other cancers. Given BMY's larger resources and extensive clinical experience, it generally has a competitive advantage over Y-mAbs, particularly in terms of funding, research capabilities, and market reach.

Eli Lilly and Company 

Eli Lilly is a diversified healthcare company that competes with Y-mAbs in areas including oncology, where it is developing antineoplastic agents. Lilly’s significant investment in research and development and its extensive portfolio of approved products establish it as a formidable competitor. The company has a broader reach in terms of market presence and product offerings, often overshadowing smaller firms like Y-mAbs. Consequently, Eli Lilly currently holds a competitive advantage over Y-mAbs due to its greater resources and established distribution networks.

Novartis AG

Novartis competes with Y-mAbs through its significant investment in the development of targeted therapies and generics. Novartis has a broader product range and a stronger international presence compared to Y-mAbs. The company also boasts a robust pipeline of innovative therapies, which include CAR-T cell therapies and targeted radioligand therapies, giving it a competitive edge. Although Y-mAbs specializes in specific treatments, Novartis' scale and diversified portfolio often overshadow Y-mAbs' offerings.